Market Overview

UPDATE: Morgan Stanley Reiterates On Amgen On New CFO

Related AMGN
EC Approves Amgen's BLINCYTO for Treatment of Adults with Philadelphia Chromosome-Negative Relapsed or Refractory B-precursor Acute Lymphoblastic Leukemia
European Commission Approves Kyprolis® (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple Myeloma
Premarket Biotech Digest: Clovis A Buy, Cellceutix Rallies, Pfizer's Avelumab Milestone (Seeking Alpha)

In a report published Tuesday, Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating on Amgen (NASDAQ: AMGN), but removed the $140.00 price target.

In the report, Morgan Stanley noted, “David W. Meline, former CFO of 3M, appointed new CFO: Meline joins from 3M where he served as CFO for the last 3 years and corporate controller for the 3 years prior to CFO. Amgen has been without a permanent CFO since Jon Peacock stepped down on 1/10/2014.

"Multi-national and P&L management experience cited as key attributes: Amgen management cited Meline's experience as a divisional CFO at GM for Brazil, Europe and North American, plus his experience at 3M as CFO for a company with operations in 70 countries, as important experience he can bring to Amgen as it expands its international operations – a goal which remains a priority for management.

"Further, Meline understands how to run a cost efficient business – another key area that Amgen management cited as important to the CFO role.”

Amgen closed on Monday at $116.40.

Latest Ratings for AMGN

Nov 2015Piper JaffrayUpgradesOverweight
Sep 2015NomuraMaintainsBuy
Sep 2015UBSUpgradesNeutralBuy

View More Analyst Ratings for AMGN
View the Latest Analyst Ratings

Posted-In: Matthew Harrison Morgan StanleyAnalyst Color Price Target Analyst Ratings


Related Articles (AMGN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters